Efficient and Reliable Cell Therapy Distribution System
Introduction
This cutting-edge cell therapy distribution system provides a streamlined, reliable method for transporting and delivering cell-based therapies to healthcare facilities. Designed to meet the unique needs of cell therapies, this system ensures that cellular products are maintained at optimal conditions during transit, preserving their efficacy and safety for patient treatment. For companies in biotechnology, pharmaceuticals, and healthcare logistics, this technology offers an invaluable solution that enhances the reach and accessibility of regenerative therapies, ensuring patients receive timely and effective care.
The Challenge: Maintaining Cell Viability During Transit
Delivering cell therapies presents complex challenges due to the fragile nature of live cells and the strict conditions required to maintain their viability. Many current logistics and distribution systems are ill-equipped to handle these unique needs, leading to potential degradation of cell quality and decreased treatment efficacy. Providers and manufacturers require a robust, tailored system that can consistently uphold strict standards for cell viability, supporting the delivery of high-quality therapies to patients across a range of settings.
Reliable and Efficient Delivery for Regenerative Medicine
This distribution system addresses these challenges by employing advanced methods to control environmental factors, monitor transit conditions, and safeguard the integrity of cell therapies throughout the entire distribution process. Using temperature regulation, real-time tracking, and stability-enhancing protocols, this system ensures that cellular products arrive in optimal condition, ready for immediate use. The technology’s efficient logistics design also allows for rapid delivery, reducing the risk of cell degradation and enhancing treatment success rates. This precise approach to distribution supports better outcomes in regenerative medicine and allows healthcare providers to expand patient access to cutting-edge therapies.
Key Benefits for Biotechnology and Healthcare Logistics
For pharmaceutical companies and biotech firms, this cell therapy distribution system offers a unique advantage in bringing their cellular therapies to a broader market with confidence. Healthcare logistics providers can leverage this technology to establish a specialized infrastructure for handling cell-based products, setting a new standard in regenerative medicine logistics. By ensuring the reliable, safe transit of cell therapies, this system supports the growing field of personalized and regenerative medicine, meeting the increasing demand for accessible, life-saving treatments that maintain efficacy from lab to clinic.
Invest in the Future of Regenerative Treatment Access
Licensing this cell therapy distribution system positions your company as a pioneer in regenerative medicine logistics. By ensuring the safe and efficient delivery of cell therapies, your business can support the global expansion of these transformative treatments. This technology is a valuable investment for companies committed to advancing patient care, promoting access to life-changing therapies, and leading in healthcare logistics innovation.
The disclosure relates to delivery systems, and corresponding methods, for selecting and delivering an allogeneic T-cell line for administration to a patient, e.g., according to the HLA profile of the patient’s somatic or diseased cells.
What is claimed is:
1. An allogeneic T-cell therapy delivery system for selecting and delivering an allogeneic T-cell line for administration to a patient in need of allogeneic T-cell therapy, comprising:
a product repository, the product repository comprising a plurality of samples comprising antigen-specific Cytotoxic T-Lymphocytes (CTLs), the CTLs of each sample having a known Human Leukocyte Antigen (HLA) profile and a known HLA restriction for said antigen;
a communication channel, the communication channel receiving patient-characteristic data, including patient identification information and the HLA profile of the patient’s somatic or diseased cells and, optionally, a physician assent to treatment of the patient with the allogeneic T-cell therapy;
an allogeneic T-cell match generator, wherein the allogeneic T-cell match generator:
determines an ordered set of cell lines from the product repository, the ordered set of cell lines prioritized at least according to a pre-determined match level between the HLA profile of the patient’s somatic or diseased cells and HLA profiles and known restriction(s) of cell lines in the product repository;
a registration module, the registration module receiving and registering the first cell line for administering to the patient; and
a shipping module, the shipping module coordinating transport of the first cell line for administration to the patient.
2. The allogeneic T-cell therapy delivery system of claim 1, wherein the allogeneic T-cell match generator stores the ordered set of cell lines in association with the patient identification information.
3. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the registration module receives and registers the physician assent to treatment of the patient.
4. The allogeneic T-cell therapy delivery system of claim 3, wherein the physician assent to treatment includes submission of a prescription.
5. The allogeneic T-cell therapy delivery system of claim 3 or 4, wherein the physician assent to treatment is received in advance of the patient’s HLA profile information.
6. The allogeneic T-cell therapy delivery system of claim 3, 4 or 5, wherein the physician assent to treatment is received simultaneously with the patient’s HLA profile information.
7. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the first cell line of the ordered set of cell lines is communicated to the patient’s physician for approval prior to transport of the first cell line.
8. The allogeneic T-cell therapy delivery system of any preceding claim, further comprising a source repository, the source repository including donor peripheral blood mononuclear cells.
9. The allogeneic T-cell therapy delivery system of any preceding claim, further comprising a T-cell target activation module, wherein the T-cell target activation module:
activates T-cells by contacting T-cells with an antigen of interest to generate antigen-specific CTLs; and
populates the product repository with the antigen-specific CTLs.
10. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the system confirms current availability of the first cell line of the ordered set of cell lines in the product repository prior to communicating or shipping the first cell line to the patient’s physician.
11. The allogeneic T-cell therapy delivery system of claim 10, wherein confirming availability of the first cell line comprises confirming availability of at least three doses of the first cell line, and the system reserves two additional doses of the first cell line in conjunction with shipping a first dose of the first cell line to the patient’s physician.
12. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the first cell line is shipped to the physician within approximately 7 days after receiving the physician assent to treatment and/or the patient characteristic data.
13. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the first cell line is shipped to the physician within approximately 6 days after receiving the physician assent to treatment and/or the patient characteristic data.
14. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the first cell line is shipped to the physician within approximately 5 days after receiving the physician assent to treatment and/or the patient characteristic data.
15. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the first cell line is shipped to the physician within approximately 4 days after receiving the physician assent to treatment and/or patient characteristic data.
16. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the first cell line is shipped to the physician within approximately 3 days after receiving the physician assent to treatment and/or patient characteristic data.
17. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the first cell line is administered to the patient within approximately 7 days after receiving the physician assent to treatment and/or patient characteristic data.
18. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the first cell line is administered to the patient within approximately 6 days after receiving the physician assent to treatment and/or patient characteristic data.
19. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the first cell line is administered to the patient within approximately 5 days after receiving the physician assent to treatment and/or patient characteristic data.
20. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the first cell line is administered to the patient within approximately 4 days after receiving the physician assent to treatment and/or patient characteristic data.
21. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the first cell line is administered to the patient within approximately 3 days after receiving the physician assent to treatment and/or patient characteristic data.
22. The allogeneic T-cell therapy delivery system of claim 7, wherein the first cell line is shipped to the physician within approximately 7 days after receiving the physician’s approval.
23. The allogeneic T-cell therapy delivery system of claim 7, wherein the first cell line is shipped to the physician within approximately 6 days after receiving the physician’s approval.
24. The allogeneic T-cell therapy delivery system of claim 7, wherein the first cell line is shipped to the physician within approximately 5 days after receiving the physician’s approval.
25. The allogeneic T-cell therapy delivery system of any preceding claim, wherein shipment to the physician, and/or administration to the patient, of the first cell line includes a first dose of the first cell line.
26. The allogeneic T-cell therapy delivery system of any preceding claim, further comprising a feedback module, the feedback module receiving information representative of the effect of administering the first cell line to the patient.
27. The allogeneic T-cell therapy delivery system of claim 26, wherein the system initiates delivery of a second cycle of the first cell line for administration to the patient when the feedback module receives a partial response.
28. The allogeneic T-cell therapy delivery system of any one of claims 26-27, wherein the system initiates delivery of another cycle of the first cell line for administration to the patient when the feedback module receives a complete response.
29. The allogeneic T-cell therapy delivery system of any one of claims 26-28, wherein the system initiates delivery of another cycle of the first cell line for administration to the patient when the feedback module receives a stable disease response.
30. The allogeneic T-cell therapy delivery system of any one of claims 27-29, wherein initiating another cycle of the first cell line includes initiating a second dose.
31. The allogeneic T-cell therapy delivery system of any one of claims 26-30, wherein the system renders a treatment complete status after receipt of two consecutive complete responses.
32. The allogeneic T-cell therapy delivery system of claim 31, wherein the system releases any doses reserved for the patient when rendering the treatment complete status.
33. The allogeneic T-cell therapy delivery system of any one of claims 26-32, wherein the system renders a treatment complete status when the feedback module receives three consecutive partial responses.
34. The allogeneic T-cell therapy delivery system of any one of claims 26-33, wherein the system selects a second cell line from the ordered set of cell lines for administering to the patient when the feedback module receives a progressive disease response or a stable disease response, and optionally communicates the second cell line for physician approval.
35. The allogeneic T-cell therapy delivery system of any one of claims 26-34, wherein the system selects a second cell line from the ordered set of cell lines for administration to the patient when the feedback module receives two consecutive stable disease responses, and optionally communicates the second cell line for physician approval.
36. The allogeneic T-cell therapy delivery system of claim 34, or 35, wherein the system confirms availability of the second cell line of the ordered set of cell lines in the product repository prior to communicating or shipping the second cell line.
37. The allogeneic T-cell therapy delivery system of claim 34, wherein confirming availability of the second cell line comprises confirming availability of at least three doses of the second cell line, and the system reserves two additional doses of the second cell line in conjunction with shipping a first dose of the second cell line to the patient’s physician.
38. The allogeneic T-cell therapy delivery system of any one of claims 34-37, wherein a first dose of the second cell line is shipped to the physician within approximately 7 days after the feedback module receives the patient response.
39. The allogeneic T-cell therapy delivery system of any one of claims 34-38, wherein a first dose of the second cell line is shipped to the physician within approximately 6 days after the feedback module receives the patient response.
40. The allogeneic T-cell therapy delivery system of any one of claims 34-39, wherein a first dose of the second cell line is shipped to the physician within approximately 5 days after the feedback module receives the patient response.
41. The allogeneic T-cell therapy delivery system of any one of claims 34-40, wherein a first dose of the second cell line is shipped to the physician within approximately 4 days after the feedback module receives the patient response.
42. The allogeneic T-cell therapy delivery system of any one of claims 34-41, wherein a first dose of the second cell line is shipped to the physician within approximately 3 days after the feedback module receives the patient response.
43. The allogeneic T-cell therapy delivery system of any one of claims 34-42, wherein a first dose of the second cell line is administered to the patient within approximately 7 days after the feedback module receives the patient response.
44. The allogeneic T-cell therapy delivery system of any one of claims 34-43, wherein a first dose of the second cell line is administered to the patient within approximately 6 days after the feedback module receives the patient response.
45. The allogeneic T-cell therapy delivery system of any one of claims 34-44, wherein a first dose of the second cell line is administered to the patient within approximately 5 days after the feedback module receives the patient response.
46. The allogeneic T-cell therapy delivery system of any one of claims 34-45, wherein a first dose of the second cell line is administered to the patient within approximately 4 days after the feedback module receives the patient response.
47. The allogeneic T-cell therapy delivery system of any one of claims 34-46, wherein a first dose of the second cell line is administered to the patient within approximately 3 days after the feedback module receives the patient response.
48. The allogeneic T-cell therapy delivery system of any one of claims 34-47, wherein the system releases any doses of the first cell line reserved for the patient in conjunction with confirming availability of the second cell line.
49. The allogeneic T-cell therapy delivery system of any one of claims 26-48, wherein the feedback module renders a treatment complete status after administration of each cell line from the ordered set of cell lines returns a stable disease response or progressive disease response.
50. The allogeneic T-cell therapy delivery system of any one of claims 26-49, wherein the system identifies cell lines receiving a partial response from the feedback module, and outputs a notification to replenish supplies of the identified cell lines when the product repository inventory of the identified cell lines falls below a threshold level.
51. The allogeneic T-cell therapy delivery system of any one of claims 26-50, wherein the system identifies cell lines receiving a complete response from the feedback module, and outputs a notification to replenish supplies of the identified cell lines when the product repository inventory of the identified cell lines falls below a threshold level.
52. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the allogeneic T-cell match generator determines an ordered set of up to four prioritized cell lines.
53. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the ordered set of cell lines from the product repository consists of a single cell line.
54. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the product repository is maintained at approximately −190° C. to −200° C.
55. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the cell line(s) is maintained at approximately −190° C. to −200° C. during transport to the physician.
56. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the cell line(s) is maintained at or below approximately −150° C. during transport to the physician.
57. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the product repository is sorted by donor source.
58. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the product repository is sorted by donor source HLA type.
59. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the CTLs in the product repository are stored in single-use vials.
60. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the patient-characteristic data includes transplant history, high resolution HLA data, and/or weight.
61. The allogeneic T-cell therapy delivery system of any preceding claim, wherein patient-characteristic data includes an HLA profile of cells from a transplanted organ.
62. The allogeneic T-cell therapy delivery system of any preceding claim, wherein patient characteristic data includes an HLA profile of transplanted allogeneic hematopoietic cells.
63. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the system is configured for implementation with patients at risk, or exhibiting symptoms, of Post-Transplant Lymphoproliferative Disorder (PTLD).
64. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the system is configured for implementation with patients at risk, or exhibiting symptoms, of EBV-associated Post-Transplant Lymphoproliferative Disorder (PTLD).
65. The allogeneic T-cell therapy delivery system of claim 63, wherein the PTLD is associated with a prior solid organ transplant in the patient.
66. The allogeneic T-cell therapy delivery system of claim 63, wherein the PTLD is associated with a prior hematopoietic cell transplant in the patient.
67. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the system is configured for implementation with patients at risk, or exhibiting symptoms, of multiple sclerosis.
68. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the system is configured for implementation with patients at risk, or exhibiting symptoms, of Cytomegalovirus infection.
69. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the system is configured for implementation with patients at risk, or exhibiting symptoms, of leukemia or solid tumor cancers.
70. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the antigen is a viral antigen.
71. The allogeneic T-cell therapy delivery system of claim 70, wherein the viral antigen is from Human papilloma virus.
72. The allogeneic T-cell therapy delivery system of claim 70, wherein the viral antigen is from Cytomegalovirus.
73. The allogeneic T-cell therapy delivery system of claim 70, wherein the viral antigen is from BK virus.
74. The allogeneic T-cell therapy delivery system of claim 70, wherein the viral antigen is from Epstein-Barr virus.
75. The allogeneic T-cell therapy delivery system of claim 70, wherein the viral antigen is from John Cunningham (JC) virus.
76. The allogeneic T-cell therapy delivery system of claim 70, wherein the viral antigen is from Merkel cell virus (MCV).
77. The allogeneic T-cell therapy delivery system of claim 70, wherein the antigen is a Wilm’s Tumor 1 (WT1) antigen.
78. The allogeneic T-cell therapy delivery system of any preceding claim, wherein antigen-specific CTLs of the product repository meet a threshold for reactivity against cells expressing the antigen.
79. The allogeneic T-cell therapy delivery system of any preceding claim, wherein said diseased cells are tumor cells.
80. The allogeneic T-cell therapy delivery system of any preceding claim, wherein the product repository lacks CTLs having a predetermined HLA characteristic.
81. The allogeneic T-cell therapy delivery system of any preceding claim, wherein CTLs of the product repository are free of pathogenic contaminants.
82. The allogeneic T-cell therapy delivery system of any preceding claim, further including a temperature sensor to monitor the temperature of the cell line(s) throughout transport of the cell line(s).
83. The allogeneic T-cell therapy delivery system of any preceding claim, further comprising a payment module, the payment module initiating payment for the cell line(s) upon receipt of the shipment by the physician.
84. The allogeneic T-cell therapy delivery system of any preceding claim, wherein an order of the first cell line includes shipment of three separate cycles of the first cell line to the physician.
85. The allogeneic T-cell therapy delivery system of claim 84, wherein a second cycle of a first cell line is shipped approximately 7 days after the first cycle of the first cell line is shipped.
86. The allogeneic T-cell therapy delivery system of claim 85, wherein a third cycle of a first cell line is shipped approximately 7 days after the second cycle of the first cell line is shipped.
87. The allogeneic T-cell therapy delivery system of any one of claims 84-85, wherein the shipment schedule for each cycle can be adjusted by the physician.
88. A method of providing a cell therapy to a patient in need of such therapy comprising:
providing a product repository comprising a plurality of samples comprising antigen-specific Cytotoxic T-Lymphocytes (CTLs), the CTLs of each sample having a known Human Leukocyte Antigen (HLA) profile and a known HLA restriction for said antigen;
receiving patient-characteristic data, including patient identification information and an HLA profile of the patient’s somatic or diseased cells;
generating an allogeneic T-cell match selection, wherein generating includes:
determining an ordered set of cell lines from the product repository, the ordered set of cell lines prioritized at least according to a pre-determined match level between the HLA profile of the patient’s somatic or diseased cells and HLA profiles and known restriction(s) of cell lines in the product repository;
optionally, receiving a physician assent to treatment of the patient with the cell therapy; and
transporting the first cell line for administration to the patient.
89. The method of claim 88, further comprising storing the ordered set of cell lines in association with the patient identification information.
90. The method of claim 88 or 89, further comprising receiving a physician assent to treatment of the patient with the cell therapy.
91. The method of any one of claims 88-90, wherein the physician assent to treatment includes submission of a prescription.
92. The method of any one of claims 88-91, wherein the physician assent to treatment is received in advance of the patient’s HLA profile information.
93. The method of any one of claims 88-92, wherein the physician assent to treatment is received simultaneously with the patient’s HLA profile information.
94. The method of any one of claims 88-93, wherein the first cell line of the ordered set of cell lines is communicated to the patient’s physician for approval.
95. The method of any one of claims 88-94, further comprising confirming current availability of a first cell line of the ordered set of cell lines in the product repository prior to communicating or transporting the first cell line to the patient’s physician.
96. The method of claim 95, wherein confirming availability of the first cell line comprises confirming availability of at least three doses of the first cell line, and reserving two additional doses of the first cell line in conjunction with transporting a dose of the first cell line to the patient’s physician.
97. The method of any one of claims 88-96, comprising transporting the first cell line for administration to the patient within approximately 7 days after receiving the physician assent to treatment.
98. The method of any one of claims 88-97, further comprising transporting the first cell line for administration to the patient within approximately 7 days after receiving patient characteristic data.
99. The method of any one of claims 88-98, further comprising transporting the first cell line for administration to the patient within approximately 7 days after receiving physician approval of the first cell line.
100. The method of any one of claims 88-99, wherein transporting to the physician, and/or administration to the patient, of the first cell line includes a first dose of the first cell line.
101. The method of any one of claims 88-100, further comprising providing a source repository, the source repository including donor peripheral blood mononuclear cells.
102. The method of any one of claims 88-101, further comprising contacting T lymphocytes with an antigen to form antigen-specific CTLs and storing the antigen-specific CTLs within the product repository.
103. The method of any one of claims 102, wherein the antigen is a viral antigen.
104. The method of claim 102, wherein the viral antigen is from Epstein-Barr virus.
105. The method of claim 102, wherein the viral antigen is from Human papilloma virus.
106. The method of claim 102, wherein the viral antigen is from Cytomegalovirus.
107. The method of claim 102, wherein the viral antigen is from BK virus.
108. The method of claim 102, wherein the viral antigen is from John Cunningham (JC) virus.
109. The method of claim 102, wherein the viral antigen is from Merkel cell virus (MCV).
110. The method of claim 102, wherein the antigen is a Wilm’s Tumor 1 (WT1) antigen.
111. The method of any one of claims 88-109, further comprising assessing the effect of the first cell line selection, wherein assessing includes:
receiving disease response feedback from the physician;
initiating a second cycle of the first cell line when at least a partial response is provided; or
providing a next sequential cell line from the ordered set of cell lines for administration to the patient, and optionally communicating the next sequential cell line for physician approval.
112. The method of claim 110, wherein initiating a second cycle of the first cell line includes initiating a second dose.
113. The method of claim 110, wherein providing a next sequential cell line includes providing a first dose of the next sequential cell line.
114. The method of claim 110, wherein the first dose of the next sequential cell line is transported to the physician within approximately 7 days after receiving disease response feedback.
115. The method of claim 110, wherein the first dose of the next sequential cell line is transported to the physician within approximately 6 days after receiving disease response feedback.
116. The method of claim 110, wherein the first dose of the next sequential cell line is transported to the physician within approximately 5 days after receiving disease response feedback.
117. The method of claim 110, wherein the first dose of the next sequential cell line is transported to the physician within approximately 4 days after receiving disease response feedback.
118. The method of claim 110, wherein the first dose of the next sequential cell line is transported to the physician within approximately 3 days after receiving disease response feedback.
119. Theethod of any one of claims 110-118, wherein the first dose of the next sequential cell line is administered to the patient within approximately 7 days after receiving disease response feedback.
120. The method of any one of claims 110-119, wherein the first dose of the next sequential cell line is administered to the patient within approximately 6 days after receiving disease response feedback.
121. The method of any one of claims 110-120, wherein the first dose of the next sequential cell line is administered to the patient within approximately 5 days after receiving disease response feedback.
122. The method of any one of claims 110-121, wherein the first dose of the next sequential cell line is administered to the patient within approximately 4 days after receiving disease response feedback.
123. The method of any one of claims 110-122, wherein the first dose of the next sequential cell line is administered to the patient within approximately 3 days after receiving disease response feedback.
124. The method of any one of claims 88-123, wherein generating an allogeneic T-cell match selection includes generating up to four prioritized cell lines.
125. The method of any one of claims 88-124, further comprising expanding the antigen-specific CTLs.
126. The method of any one of claims 88-125, further comprising assessing allo-reactivity of the antigen-specific CTLs and excluding or discarding CTLs exhibiting allo-reactivity above a predetermined threshold prior to adding the cells to the product repository.
127. The method of any one of claims 88-126, further comprising assessing the anti-antigen reactivity of the antigen-specific CTLs, and adding them to the product repository if the CTLs are determined to meet a threshold for anti-antigen reactivity.
128. The method of any one of claims 88-127, further comprising evaluating the HLA profile of the antigen-specific CTLs of the product repository and storing the HLA profile in connection with each sample of CTLs.
129. The method of any one of claims 88-128, further comprising administering the cell therapy to a patient at risk, or exhibiting symptoms, of Post-Transplant Lymphoproliferative Disorder (PTLD).
130. The method of any one of claims 88-128, further comprising administering the cell therapy to a patient at risk, or exhibiting symptoms, of EBV-associated Post-Transplant Lymphoproliferative Disorder (PTLD).
131. The method of any one of claims 88-127, further comprising administering the cell therapy to a patient at risk, or exhibiting symptoms, of multiple sclerosis.
132. The method of any one of claims 88-127, further comprising administering the cell therapy to a patient at risk, or exhibiting symptoms, of leukemia, or a solid tumor cancer.
133. The method of any one of claims 88-127, further comprising administering the cell therapy to a patient at risk, or exhibiting symptoms, of CMV infection.
134. The method of any one of claims 88-127, further comprising administering the cell therapy to a patient at risk, or exhibiting symptoms, of a hematological disorder characterized by expression of a Wilm’s Tumor 1 antigen.
Share
Title
Systems and methods for distributing cell therapies
Inventor(s)
Derrell D. Porter
Assignee(s)
Atara Biotherapeutics Inc
Patent #
20200350049
Patent Date
November 5, 2020